Under the agreement, Separex, under a license of Stanipharm, will develop a manufacturing process, scalable to industrial volumes, to concentrate the Omega-3 fatty acid, eicosapentaenoic acid (EPA), which Photonz extracts from fermented microalgal biomass.
Photonz’s proprietary processes produce the EPA by fermenting a marine microalgal clone (improved by strain selection not genetic engineering) to produce a biomass rich in lipids from which it extracts the Omega-3.
The agreement follows two other significant achievements, announced last year, in which Photonz proved the feasibility of its continuous fermentation system and then harvested the first batch of algal biomass from its prototype industrial plant. The plant is now producing on a small industrial scale and has the potential to produce tonnes of algal material per year. The lipids it produces will be used by Separex to produce concentrated EPA. Photonz is, in parallel, targetting the development of downstream purification processes to produce high purity EPA, suitable for pharmaceutical applications, including novel therapeutics.










